Inflammatory Markers and Resistant Depression

Not Applicable

• Conditions: Depression
• Interventions: Procedure: blood sample; Behavioral: psychometric scales

• Registration Number: NCT02847533
• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Brief Summary

This study focuses on blood inflammatory markers (pro-inflammatory cytokines, anti-inflammatory cytokines, monocytes costimulation molecules) in patients with resistant unipolar depression in comparison with non-resistant unipolar depressed patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-07
• Study First Submitted: 2016-07-21
• Study First Submitted QC: 2016-07-25
• Last Update Submitted: 2016-07-25
• Study First Posted: 2016-07-28
• Last Update Posted: 2016-07-28
• Study Start: 2016-09
• Primary Completion: 2018-06
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

• group 1: Patients with resistant MDD (at least 2 failed treatments for the current episode) ,current treatment with IRS or IRSNA,
• group 2: patients with MDD remission after response to an antidepressant treatment.

Exclusion Criteria

• comorbid somatic or psychiatric disorders: chronic or acute inflammatory diseases, previous treatment with brain stimulation for the current episode, legal protection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
resistant depression	psychometric scales	patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
resistant depression	blood sample	patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
non resistant depression	blood sample	patients in remission from unipolar depressive disorder
non resistant depression	psychometric scales	patients in remission from unipolar depressive disorder

Primary Outcome Measures

Name	Time	Method
plasmatic concentration of Interleukin 6	at patient inclusion

Secondary Outcome Measures

Name	Time	Method
concentration of proinflammatory cytokine	at patient inclusion	Expression intensity of monocytes costimulation molecules
concentration of antiinflammatory cytokine	at patient inclusion
plasmatic concentration of Retinoid X receptor signaling pathway	at patient inclusion
Expression rate of monocytes costimulation molecules	at patient inclusion
functional polymorphisms of expression genes of inflammatory proteins	at patient inclusion

Trial Locations

Locations (1)

CHU Besançon; 🇫🇷 Besançon, France